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The phosphatonin pathway: New insights in phosphate home-
ostasis. Serum phosphate concentrations are maintained within
a defined range by processes that regulate the intestinal absorp-
tion and renal excretion of inorganic phosphate. The hormones
currently believed to influence these processes are parathy-
roid hormone (PTH) and the active metabolite of vitamin
D, 1a,25-dihydroxyvitamin D (1a,25(OH)2D). A new class of
phosphate-regulating factors, collectively known as the phos-
phatonins, have been shown to be associated with the hy-
pophosphatemic diseases, tumor-induced osteomalacia (TIO),
X-linked hypophosphatemic rickets (XLH), and autosomal-
dominant hypophosphatemic rickets (ADHR). These factors,
which include fibroblast growth factor 23 (FGF23) and se-
creted frizzled-related protein 4 (FRP4), decrease extracellular
fluid phosphate concentrations by directly reducing renal phos-
phate reabsorption and by suppressing 1a,25(OH)2D formation
through the inhibition of 25-hydroxyvitamin D 1a-hydroxylase.
The role of these substances under normal or pathologic condi-
tions is not yet clear. For example, it is unknown whether any
of the phosphatonins are directly responsible for the decreased
concentrations of 1a,25(OH)2D observed in chronic and end-
stage kidney disease or whether they are induced in an attempt
to correct the hyperphosphatemia seen in late stages of chronic
renal failure. Future experiments should clarify their physio-
logic and pathologic roles in phosphate metabolism.
The control of phosphorus concentrations through in-
testinal absorption and renal conservation is critical to
several biologic processes, including mineral metabolism,
skeletal development, energy transfer, cellular signaling,
and the regulation of protein function. Phosphorus is
a major component of bone mineral, membrane phos-
pholipids, energy-storing nucleotides, and nucleic acids.
Regulation of critical biochemical processes via phospho-
rylation or dephosphorylation is an important mechanism
by which various cells control their activity. Inorganic
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phosphorus (Pi) is an important component of hydroxya-
patite that is deposited at the mineralization front in cor-
tical and trabecular bone [1–5]. A deficiency of Pi results
in a defect in the deposition of mineral and the presence
of unmineralized osteoid that characterizes osteomalacia
in adults and rickets in developing animals and humans
[1, 6].
A growing body of evidence now suggests that, in
addition to parathyroid hormone (PTH) and the vi-
tamin D endocrine system, other factors may play a
role in the general maintenance of phosphate home-
ostasis. These factors, loosely termed the “phospha-
tonins,” have been discovered through studies of the
phosphate-wasting disorders: tumor-induced osteomala-
cia (TIO), X-linked hypophosphatemic rickets (XLH),
and autosomal-dominant hypophosphatemic ricketf
(ADHR). This review will illustrate how the recent
discovery and characterization of these factors have
begun to elucidate a novel phosphate homeostatic
mechanism(s).
REGULATION OF PHOSPHATE METABOLISM
The circulating concentration of phosphate is depen-
dent on the dietary Pi intake, intestinal absorption, renal
filtration and reabsorption, and exchange from intracellu-
lar and bone reservoirs. Figure 1 shows the metabolism of
Pi in humans. A normal human ingests approximately 1.5
to 2 g of phosphorus per day (20 mg/kg/day). Of this, ∼1 to
1.2 g (16 mg/kg/day) is absorbed in the proximal intestine
and ∼200 mg (3 mg/kg/day) is secreted into the intesti-
nal lumen giving a net absorption of approximately 1 g
(13 mg/kg/day). The absorbed phosphorus enters an
extracellular fluid pool and moves in and out of
bone as needed (∼3 mg/kg/day). Approximately 1 g
(13 mg/kg/day) is excreted by the kidneys such that equiv-
alent amounts of phosphorus are absorbed and excreted.
Thus, under physiologic conditions, the intestine and the
kidney function in concert to maintain phosphorus home-
ostasis and normal plasma Pi concentrations (∼2.5 to
4.5 mg/dL). Patients with hypophosphatemic disorders
such as XLH, ADHR, and TIO may have circulating
1
2 Schiavi and Kumar: Phosphatonins and phosphate Someostasis
Intake
20 mg/kg/day
16 mg/kg/day
intestinal
absorption
3 mg/kg/day
intestinal
juices 
Feces
7 mg/kg/day
ECF phosphorus
pool 
Bone
Kidney
13 mg/kg/day
3 mg/kg/day 
Fig. 1. Phosphorus metabolism.
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Fig. 2. Influence of phosphate on parathyroid hormone (PTH) and
vitamin D synthesis and activity. Pi is inorganic phosphorus.
levels as low as 2 mg/dL, whereas patients with
declining renal function can have levels that exceed
6 mg/dL.
The major known hormones regulating phosphorus
metabolism are 1a,25(OH)2D3 and PTH [1, 2, 4, 7–13].
As described below, PTH inhibits renal phosphate reab-
sorption and indirectly increases intestinal phosphorus
absorption by stimulating the synthesis of 1a,25(OH)2D.
Phosphorus has a direct stimulatory effect on the secre-
tion of PTH and elevated serum Pi is believed to be an
important contributor to the hyperparathyroidism asso-
ciated with late stages of chronic renal disease (Fig. 2)
[14–18].
1a,25(OH)2D3 increases intestinal Pi absorption and
renal Pi reabsorption [2, 9, 10, 19–35]. The formation of
the active form of vitamin D3, 1a,25(OH)2D3, is reg-
Table 1. Factors affecting phosphate reabsorption in the proximal
tubule
Factors that decrease Factors that increase
Pi reabsorption Pi reabsorption
Phosphate loading Phosphate depletion
Parathyroid hormone/cAMP Parathyroidectomy
Volume expansion Volume contraction
Hypercalcemia Hypocalcemia
Carbonic anhydrase inhibitors 1a,25(OH)2D3
Glucose and alanine Growth hormone
Acid-base disturbances Insulin-like growth factor
Increased bicarbonate
Hypercapnia
Metabolic inhibitors
Arsenate
Fibroblast growth factor 23
Frizzled receptor protein 4
Abbreviations are: Pi, inorganic phosphorus; cAMP, cyclic adenosine
monophosphate.
ulated by dietary Pi, circulating serum Pi concentra-
tions and PTH. Extracellular Pi regulates 25(OH)D3
1a-hydroxylase [1a (OH)ase] synthesis and activity such
that low Pi concentrations increase and high Pi concen-
trations inhibit its synthesis and activity (Fig. 2) [2–4, 10,
19–21, 23–28, 35–39]. This regulation occurs via a mech-
anism that is independent of PTH as well as the sodium
phosphate transporter, NaPi IIa [40]. The adaptation to
low Pi diets in the vitamin D endocrine system appears
to require the presence of growth hormone and insulin-
like growth factors [41–48]. PTH increases synthesis of
1a,25(OH)2D3 by increasing the activity of 1a (OH)ase
[49, 50].
Regulation of phosphate homeostasis in the kidney oc-
curs primarily in the proximal tubule and is controlled
by a variety of factors that either increase or decrease
Pi reabsorption (Table 1) [2–5, 7–13, 19, 20, 22, 23, 51–
78]. Plasma inorganic phosphate is freely filtered at the
glomerulus. Approximately 80% of filtered phosphate
is reabsorbed along with sodium through specific co-
transporters, NaPi IIa, located in the proximal tubule.
NaPi IIa is a member of one of three distinct families of
sodium phosphate cotransporters (Table 2) [11, 12, 79,
80]. Mice deficient in NaPi IIa have about an 80% reduc-
tion in proximal renal phosphate reabsorption, confirm-
ing the major role of this specific transporter in phosphate
homeostasis [81].
Regulation of phosphate reabsorption in the kidney
is achieved primarily by controlling the number of the
NaPi IIa cotransporters present on the surface of the
proximal brush border membranes. Current evidence
suggests that acute decreases in dietary Pi lead to recruit-
ment of existing NaPi IIa transporters from an intracel-
lular pool [82, 83], whereas chronic changes in dietary Pi
regulate NaPi IIa through transcription-dependent meth-
ods [83, 84]. Chronic administration of 1a,25(OH)2D3
and PTH modulate NaPi IIa mRNA and protein [85,
86]. Elevated PTH rapidly reduces the number of
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Table 2. The three families of Na+/Pi cotransporters [11, 12, 72]
Type II Type III
Family Type I IIa IIb IIc Pit1 (Glvr1) Pit2 (Ram1)
Amino acids ∼465 ∼640 ∼690 ∼640 679 656
Substrate Pi, anions Pi Pi Pi Pi Pi
Affinity for Pi 0.3 mmol/L 0.1–0.2 mmol/L 0.05 mmol/L 0.07 mmol/L 0.024 mmol/L 0.025 mmol/L
Na+:Pi >1:1 3:1 3:1 2:1 3:1 3:1
Expression Kidney, liver Kidney Small intestine, lung Kidney Ubiquitous Ubiquitous
Regulation No PTH, Pi Pi Pi Pi, IGF-1 Pi
Abbreviations are: Pi, inorganic phosphorus; PTH, parathyroid hornone; IGF-1, insulin-like growth factor-1.
NaPi IIa transporters by inducing surface retrieval and
subsequent lysosomal degradation [7, 8, 11, 12, 57, 67–
73, 87–101]. The mechanism of PTH-induced retrieval
involves stimulation of at least two signal transduction
pathways that converge on the mitogen-activated pro-
tein (MAP) kinase, extracellular regulated kinase (ERK)
[102, 103]. It is currently unclear how stimulation of ERK
triggers internalization of NaPi IIa. Targeted disruption
of NHERF-I, a cytoplasmic docking protein known to
assemble multiple protein signaling complexes, results
in decreased brush border NaPi IIa expression and re-
duced renal phosphate reabsorption [104]. The demon-
stration that NHERF-I interacts with NaPi IIa further
supports the possibility that this protein may be an im-
portant intermediate in PTH action [105]. However, a re-
cent study suggests that NHERF-I, while important for
trafficking of NaPi IIa to the membrane, is not involved in
PTH-induced membrane retrieval [106, 107].
Intestinal absorption of phosphate occurs through
both nonregulated passive transport and regulated active
mechanisms. The type IIb sodium-phosphate cotrans-
porter located predominantly in the jejunum mediates
active intestinal phosphate transport and appears to be
regulated at the transcriptional level by 1a,25(OH)2D3
[90]. It, however, does not undergo retrieval from the
membrane in response to PTH. The mechanisms con-
trolling the release of phosphate and calcium from
intracellular and bone pools are poorly understood and
may involve specific regulation of the type III sodium-
phosphate transporters, Glvr1 (Pit1) and Ram1 (Pit2)
[108, 109].
This well-defined paradigm for phosphate regulation
may be extended to include the function of one or more
members of the emerging class of phosphate regulating
proteins, the “phosphatonins” [74–79, 110–115]. As we
will show in subsequent sections, the “phosphatonins”
[fibroblast growth factor 23 (FGF23) and frizzled-related
protein 4 (FRP4)] also play roles in modulating renal
phosphorus reabsorption and 1a,25(OH)2D3 production.
Insufficient information prohibits a clear understand-
ing of the interplay between phosphatonins, PTH, and
the vitamin D pathway. However, recent and tantaliz-
ing new data have provided enough evidence that fo-
cused studies of the phosphatonins are not only relevant
but necessary for a complete understanding of phosphate
homeostasis.
THE PHOSPHATONINS
A group of pathologic conditions exist in which
phosphate levels are altered without significant net
changes in serum concentrations of calcium, PTH, and
1a,25(OH)2D3. These diseases, which are characterized
by hypophosphatemia, hyperphosphaturia, and defec-
tive bone mineralization include TIO, XLH, and ADHR
[75–77, 110–116]. The observation that patients with
these diseases generally have normal serum concentra-
tions of PTH and calcium, in association with low or
normal serum 1a,25(OH)2D3 concentrations, is unex-
pected based on the current understanding of phosphate
regulation. Early studies provided compelling evidence
that a circulating humoral factor, referred to as “phos-
phatonin,” is likely responsible for the altered phos-
phate regulation observed in these syndromes [110–120].
Tumors associated with osteomalacia cause hypophos-
phatemia when implanted into athymic mice and condi-
tioned media from tumors cultured in vitro specifically
reduced phosphate uptake in renal epithelial cells [110].
These studies suggested that such tumors secrete a fac-
tor(s) that can act at a distance to inhibit renal phos-
phate reabsorption. Evidence that a humoral factor(s) is
associated with XLH is derived from studies in hyp mice,
the mouse model of XLH. Parabiosis experiments be-
tween hyp and normal mice show that a factor present
in the circulation of hyp mice causes hypophosphatemia
in the normal mouse [117, 118]. This factor is not PTH,
as parathyroidectomy of the hyp mouse (in the parabi-
otic pair) does not influence the reduction in serum Pi in
the normal mouse. In addition, transplantation of a kid-
ney from a normal mouse into a hyp mouse does not
correct the hyperphosphaturia and hypophosphatemia
present in the recipient; conversely, the reverse procedure
is not associated with any alterations in Pi metabolism
in the normal mouse [119]. Additionally, cultures of hyp
mouse proximal tubules transport phosphate normally
[120]. These data are consistent with the presence of a
circulating phosphaturic factor(s) in hyp mice. Although
analogous studies cannot be performed for ADHR,
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the similarity of symptoms associated with ADHR,
XLH, and TIO suggest that an increase in expression
and/or activity of a phosphatonin is a common feature
among these syndromes. Since these early studies, several
genomic and proteomic strategies have been utilized in
the search for these molecules. Surprisingly, these stud-
ies identified three proteins that are associated with one
or more of these syndromes, FGF23, FRP4, and matrix
extracellular phosphoglycoprotein (MEPE), that may
each possess some or all of the properties associated with
phosphatonin.
THE SEARCH FOR PHOSPHATONIN
A positional cloning approach was used to discover the
affected gene associated with ADHR. Analysis of a large
affected family indicated that the gene responsible for
this disease was located on chromosome 12p13.3 [121].
Mutations within a new gene, FGF23, with significant
homology to genes within the FGF family, segregated
exclusively with ADHR [122]. In four ADHR families,
three missense mutations were found clustered within a
small region of 2 amino acids. This observation together
with the fact that ADHR is an autosomal-dominant dis-
order suggested that these mutations might result in a
gain of function for FGF23.
The impact of these mutations on the structure of
FGF23 became clear as several groups expressed the
wild-type form of FGF23 in vitro. In addition to the ex-
pected 30 kD protein encoded by the full-length FGF23
gene, two smaller fragments were also detected. Expres-
sion of FGF23 protein containing carboxy [123–126] and
amino epitope tags [127] revealed that a portion of the
secreted FGF23 was processed into two discrete frag-
ments of 18 and 12 kD. The sizes of these fragments and
their deduced amino terminal sequences are consistent
with cleavage at a predicted site for a pro-convertase
type enzyme, RXXR [122–125]. Importantly, the iden-
tified ADHR mutations, R176Q, R179W, and R179Q,
replace critical R residues within the consensus cleavage
site of FGF23 (176-RHTR-179) [122, 125–127]. Process-
ing of the mutated protein is inhibited in vitro [124, 126,
128] supporting the hypothesis that ADHR mutations in-
terfere with FGF23 processing (Fig. 3). Although there is
no direct evidence that altered activity or levels of a circu-
lating factor(s) results in ADHR, the similarity between
this syndrome, XLH, and TIO where there is evidence
for a circulating factor, provides a compelling case that
FGF23 encodes phosphatonin activity.
Because ADHR shares similar clinical and biochem-
ical symptoms with the tumor-associated disease, TIO,
White et al [123] examined FGF23 RNA expression in
tumors associated with osteomalacia. Northern blot anal-
ysis suggested that FGF23 mRNA was expressed at rela-
tively high levels in five tumors isolated from TIO patients
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ADHR mutations
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PHEX No cleavage in XLHby defective PHEX
30 kD
18 kD 12 kD
Mutations in ADHR
increase activity 
 
Consensus FGFR
binding site
Proconvertase
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Fig. 3. Model depicting fibroblast growth factor 23 (FGF23) process-
ing and potential PHEX cleavage in normal, autosomal-dominant hy-
pophosphatemic rickets (ADHR) or X-linked hypophosphatemic rick-
ets (XLH) individuals.
and Western blot analysis further revealed detectable lev-
els of FGF23 in a sixth tumor. This observation linking
FGF23 to two related diseases, TIO and ADHR, further
supported the hypothesis that FGF23 is phosphatonin.
Despite the striking evidence correlating FGF23-
associated changes with phosphaturic disorders, the
assignment of phosphatonin becomes uncertain when dif-
ferential expression studies are considered [125, 128, 129].
Although FGF23 was identified in two out of three of
these studies, expression profiling also identified at least
two additional phosphatonin candidates and other genes
potentially involved in the phosphatonin pathway. These
approaches have been based on the premise that a phos-
phaturic protein(s) and/or the gene(s) encoding it, is over-
expressed in specific tissues from diseased individuals.
Evidence that tumors causing TIO secrete a phosphate-
lowering activity [110] prompted several investigators to
utilize these tumors as a source tissue for the identifica-
tion of phosphatonin. Rowe et al [130] were the first to
identify a novel TIO-associated gene encoding a potential
phosphatonin candidate. A TIO tumor-derived cDNA
library was screened with antibodies raised against circu-
lating proteins in sera from a TIO patient. The sera had
been extensively preabsorbed against normal human sera
to enrich for antibodies that would specifically recognize
proteins differentially expressed in sera of TIO patients.
The distinct advantage to this strategy was that it detected
only those overexpressed genes that encode circulating
proteins. Using this approach, MEPE was identified as
a novel tumor-associated product. The observations that
MEPE is present in the circulation of TIO patients ap-
pears to be expressed abundantly in TIO tumors, and is a
previously uncharacterized secreted protein, are consis-
tent with the possibility that MEPE is phosphatonin.
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Gene expression profiling of TIO tumors using two
distinct strategies further extended this work [125, 129].
In each case, several genes, including FGF23 and MEPE,
were identified that were specifically associated with TIO.
Shimada et al [125] generated two cDNA libraries from
a single TIO tumor and adjacent normal bone tissue.
Probes specific for each library were also generated using
subtractive hybridization and used to specifically probe
each library. Out of a total of 32,000 clones isolated,
456 clones were unique to the TIO tumor-derived li-
brary. Proteins encoded by the selected genes included
dentin matrix protein 1 (DMP1), heat shock protein 90
(HSP90), osteopontin (OPN), fibronectin, MEPE, and
FGF23. DMP1 and HSP90 were the most abundant can-
didate proteins identified, whereas significantly fewer
clones represented FGF23 and MEPE. Although each of
the secreted proteins identified could theoretically func-
tion as phosphatonin, the preexisting evidence linking
FGF23 to ADHR [122] and MEPE to TIO [130] contin-
ued to place these two genes high on the list of potential
phosphatonin candidates.
A more extensive analysis of TIO-specific genes was
provided by serial analysis of gene expression (SAGE)
[129]. In this strategy, gene expression profiles were
obtained from a variety of tumors resected from TIO
patients and histologically matched control tumors that
were not associated with TIO. Genes that were over-
expressed in the TIO tumors relative to the control
tumors were selected and further validated by microarray
analysis using RNA isolated from a broad panel of addi-
tional control and TIO tumors. This approach ensured
that phosphatonin would be selected if it were encoded
by a gene induced by a tumor-specific autocrine factor.
An additional advantage to this strategy was that a high
degree of stringency was imposed on gene selection by
identifying genes differentially expressed between multi-
ple control and TIO tumors.
In addition to MEPE, DMP1, and FGF23, SAGE
identified other TIO-associated genes [129]. These genes
included FRP4, transforming growth factor-b1 (TGF-
b1), secreted serine protease (SP11), a synaptotagmin-
like protein, GLVR1, and ANK. Furthermore, the SAGE
analysis demonstrated that several genes reported to be
linked to TIO by the Japanese group were not specifically
associated with the TIO phenotype [129]. For example,
OPN and fibronectin were elevated in several normal and
TIO-associated tumors.
Of interest is the observation that many of the
genes identified by SAGE encode proteins associated
with osteoblast/chondrocyte differention and/or min-
eral metabolism. For example, ANK encodes a trans-
porter for pyrophosphate, a mineralization inhibitor [131,
132]. ANK-deficient mice have a progressive form of
arthritis that is accompanied by ectopic mineralization.
GLVR1(PIT1) encodes a ubiquitously expressed type
III sodium phosphate transporter (Table 2) that has
been implicated in osteoblast mineralization [108, 109,
133, 134]. TGF-b1 is an important osteoblast differenti-
ation factor and increases expression of GLVR1 mRNA
[135]. These and other SAGE-identified genes may repre-
sent downstream components of phosphatonin-regulated
pathways. The observation that phosphatonin(s) may
have induced tumor expression of osteoblast-related
genes provides evidence that phosphatonins may have
direct actions on bone.
ASSESSING PHOSPHATONIN ACTIVITY
The genomic and proteomic approaches described
above identified multiple genes associated with hy-
pophosphatemic disorders. Each of the encoded secreted
proteins (or posttranslationally modified variations of the
proteins), represent potential phosphatonin candidates.
Alternatively, these genes could encode regulators of
phosphatonin expression or activity, or represent genes
induced by phosphatonin.
The ability to unambiguously identify the gene(s) that
encodes phosphatonin is clearly dependent on the defi-
nition of its activity. Kumar [77] proposed that phospha-
tonin should be identified when the following criteria are
met. First, the protein must inhibit phosphate uptake in
vitro and in vivo. Second, the factor must inhibit the for-
mation of 1,25(OH)2D3 in vivo and in vitro. Third, the
protein should be expressed in tumor tissues responsible
for the syndrome. Fourth, the concentrations of phos-
phatonin should be elevated in the serum of patients with
each of the disorders. In the case of TIO, surgical resection
of the tumor should result in decreased serum concentra-
tions. Finally, urinary cyclic adenosine monophosphate
(cAMP) excretion should be normal. It is important to
point out that these criteria also assume that a single pro-
tein is responsible for the symptoms associated with TIO,
XLH, and ADHR. However, the evidence that multiple
proteins participate in the pathophysiology of these phos-
phaturic diseases raises the possibility that phosphatonin
activity is due to the combined actions of minimally three
proteins.
FGF23
Several approaches have been used to assess the func-
tion of FGF23. We have demonstrated that both the na-
tive and a mutated form found in ADHR patients inhibits
phosphate but not alanine, glucose, or sulfate uptake in
renal epithelial cells in vitro [124]. Picomolar concentra-
tions of FGF23 inhibited phosphate transport suggest-
ing that FGF23 may function at concentrations that fall
within the normal range for other cytokines (Fig. 4A)
[124, 136]. Differences in clonal cell lines and assay con-
ditions may account for discrepancies in the ability of
various groups to detect FGF23 activity in vitro.
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Fig. 4. Effect of fibroblast growth factor 23
(FGF23) or frizzled-related protein 4 (FRP4)
on phosphate transport. (A) In vitro effects
of FGF23 ( ) or FRP4 () on inorganic phos-
phorus transport (Pi) in opossum kidney cells.
(B) FGF23 effects on the percent fractional
Pi excretion. Mice were infused for 2 hours
with vehicle (), 0.5 lg FGF23/2 hour (),
or 5 lg FGF23/2 hours (). (C) FRP4 effects
on the percent fractional Pi excretion. Mice
were infused for 2 hours with vehicle (),
0.05 lg FRP4/2 hour (), or 0.5 lg FRP4/2
hours.
Intraperitoneal administration of recombinant FGF23
in normal mice induced phosphaturia and a small but
significant decrease in serum phosphate levels [125].
There was no effect when purified amino or carboxyl
FGF23 fragments were injected suggesting that the in-
tact molecule is responsible for biologic activity. In mice
injected intravaneously with a dose of 5 lg of intact
FGF23, a 20% to 25% decrease in serum phosphate and a
reduction in renal NaPi IIa protein was observed within
8 hours. 1a,25(OH)2D3 levels were also reduced but sta-
tistically significant changes were observed within 2 hours
and reached a maximum decrease within 9 hours after ad-
ministration of FGF23 [abstract; Shimada T, J Bone Miner
Res 17:S425, 2000]. There was no detectable difference in
the levels of calcium and PTH. These temporal relation-
ships prompted investigators to suggest that the primary
role of FGF23 is to control 1a,25(OH)2D3 production,
and that the effects on phosphate transport are of sec-
ondary importance. Our data demonstrate that FGF23
inhibits phosphate transport in vitro within 3 hours
(Fig. 4A) and increases phosphate excretion as quickly
as 11/2 hours after intravenous infusion of FGF23
(Fig. 4B). It is possible that FGF23 promotes mobi-
lization of phosphate from bone or intracellular stores
in addition to renal excretion, such that a lag pe-
riod is observed before reductions in serum Pi can be
observed.
Long-term exposure to FGF23 by implantation
of FGF23-expressing Chinese hamster ovary (CHO-
FGF23) cells into athymic nude mice, induced more
severe hypophosphatemia, osteomalacia, decreased
1,25(OH)2D3 levels, and a corresponding decrease in
25(OH)D3 1a-hydroxylase mRNA. There was no in-
crease in urinary cAMP concentrations or alterations in
the excretion of amino acids [125]. Studies of transgenic
mice expressing FGF23 provide further evidence that this
factor contributes to many if not all the laboratory abnor-
malities associated with hypophosphatemic, hyperphos-
phaturic disorders [abstract; Shimada T, J Bone Miner Res
16:S151, 2001]. FGF23 transgenic mice had significantly
reduced serum phosphate and 1a,25(OH)2D3 concentra-
tions. Furthermore, skeletal abnormalities, including re-
tarded growth, increased osteoid, and curvature of the
spine, were also observed.
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In vivo experiments also revealed that in addition
to inhibiting protein processing, the ADHR mutation
results in enhanced phosphaturic activity [137, 138]. Bai
et al [137] examined the effects of implanted CHO
tumors expressing either wild-type FGF23 or the ADHR
mutant, FGF23R176Q, on serum and urine phos-
phate levels. Although approximately equivalent lev-
els of each form of FGF23 protein were produced,
FGF23R176Q expression was associated with a greater
increase in Pi excretion, decreased serum Pi, and reduced
1,25(OH)2D3 concentrations. Interestingly, these experi-
ments also revealed that long-term expression of FGF23
or FGF23R176Q resulted in increased PTH concentra-
tions. Experiments in which naked DNA was injected
into rats also demonstrated profound effects of all three
ADHR mutants on serum phosphate levels and renal
NaPi IIa protein levels [138]. These experiments, which
differed in both the method of expressing FGF23 and
the animal species, failed to demonstrate the changes in
serum Pi that have been observed in mice.
The development of enzyme-linked immunosorbent
assays (ELISA) allowing the measurement of FGF23 in
the serum of normal and hypophosphatemic patients has
provided somewhat unexpected results. As mentioned
above, FGF23 is expressed as an intact 30 kD form or
processed fragments of 18 and 12 kD. Detectable lev-
els of FGF23 were measured in normal individuals using
an assay recognizing an epitope within the carboxy end
(recognizes both the 30 and 12 kD forms of the protein)
[139] and by an assay developed to detect only the 30 kD
FGF23 protein [140]. Increased FGF23 levels were de-
tected in most but not all patients with XLH or TIO
[139, 140]. In TIO patients who exhibited elevated
FGF23 concentrations, circulating levels returned to
within the normal range upon removal of the tumor
[139, 140]. Singh and Kumar [141] demonstrated that
patients with humoral hypercalcemia of malignancy had
elevated serum FG23 concentrations and patients with
hyperparathyroidism had slightly increased FGF23 con-
centrations. These elevations are not correlated with the
decrease in serum phosphate or 1a,25(OH)2D3 concen-
trations. The finding that elevated levels of FGF23 are not
always linked to hyperphosphaturic hypophosphatemic
disorders is surprising and implies that FGF23 is not the
sole factor contributing to the pathogenesis of these dis-
orders.
The mechanism by which FGF23 alters phosphate
homeostasis is not entirely clear. In vivo studies demon-
strated that NaPi IIa protein is reduced after chronic
FGF23 administration, raising the possibility that simi-
lar to PTH, FGF23 may induce NaPi IIa internalization
and degradation [125, 138]. It is assumed that FGF23
may elicit these and other changes through binding to a
membrane-associated receptor such as one of the known
FGF receptors (FGFRs). Consistent with the presence
of a FGFR binding domain within the amino portion of
FGF23 is the finding that FGF23 binds to known FGFRs
in vitro [abstract; Pragnell M, J Am Soc Nephrol 12:600A,
2001] [136]. However, in vivo validation will be required
to convincingly demonstrate that FGF23 elicits its actions
through a known FGFR. Binding and signaling by other
FGFs in vivo is dependent not only on the presence of
the appropriate receptor but the expression of specific
proteoglycans on the cell surface [142]. In vitro systems
may not adequately reflect the in vivo conditions with
regard to proteoglycan and receptor distribution. Thus,
differences observed in the ability of heparin to influence
the activity of FGF23 within in vitro uptake assays may
be due to differential proteoglycan expression of various
opossum kidney cell clones used in the phosphate trans-
port assay [124, 125, 129, 136]. However, the observation
that a tyrosine phosphorylation event occurs in response
to FGF23 is consistent with the possibility that FGF23 ac-
tions are elicited at least in part through a classic FGFR
[136].
FRP4
Additional evidence suggests that at least in the case
of TIO, FGF23 may not be the only phosphaturic protein
involved in the disease pathogenesis. We have demon-
strated that secreted FRP4, a second factor overex-
pressed in TIO tumors, also has phosphate-lowering
activity [56, 129]. FRP4 is a posttranslationally modi-
fied protein that has a predicted molecular weight of
∼40,000 kD but migrates on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) with a
Mr of ∼48,000 kD due to glycosylation. It is a mem-
ber of a protein family consisting of eight members that
contain a cysteine-rich domain with high homology to
the extracellular domain of membrane-bound Wnt re-
ceptors, the frizzled proteins [143, 144]. The Wnt pro-
teins play an exceptionally important and prominent role
in diverse biologic processes ranging from embryo de-
velopment and cancer formation to neurodegenerative
disease [145]. There are numerous secreted Wnt ligands
of which 19 have been identified in the human genome.
These ligands transduce paracrine signals through ten or
more membrane-bound receptors, the frizzled proteins.
Some but not all FRPs have been shown to bind Wnts
and antagonize their actions by serving as a soluble decoy
[146, 147]. Interestingly, there appears to be interconnec-
tions between Wnt signaling pathways and other growth
factor pathways such as Notch, bone morphogenetic pro-
teins (BMPs), and FGFs [144, 148, 149]. It is appealing
to speculate that there may be direct link between the
actions of FRP4 and FGF23.
FRP4 inhibits phosphate transport in the classic opos-
sum kidney cell assay and is phosphaturic in vivo
(Fig. 4A and C) [56]. Infusion of FRP4 into mice or
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rats caused increased phosphate excretion within 2 hours
and decreased serum Pi within 8 hours of administra-
tion. 1a,25(OH)2D3 serum concentrations were not al-
tered despite FRP4-induced hypophosphatemia. FRP4
did not alter urinary cAMP levels but caused increased
phosphorylation of renal b-catenin levels, suggesting that
this protein may function by opposing the actions of a
Wnt. Finally, circulating levels of FRP4 were identified
in normal individuals and a patient with TIO. Thus, the
severe phosphaturia associated with TIO is likely due to
overexpression of at least two proteins, FGF23 and FRP4.
It remains to be determined whether FRP4 is also over-
expressed in XLH and ADHR patients and contributes
to the pathophysiology of these diseases.
MEPE
MEPE encodes a glycosylated protein of approxi-
mately 60 kD. Based on gene structure, MEPE appears
to be a member of a growing family of extracellular ma-
trix proteins called small integrin-binding ligand N-linked
glycoproteins (SIBLINGs). Other family members
include OPN, DMP1, and dentin sialoprotein (DSSP)
[150]. Although MEPE is clearly overexpressed in the
tumors of patients with TIO, the data with respect to
its role in this syndrome are unclear. Antisera from a
patient harboring a TIO tumor blocked an apparent
inhibition of phosphate uptake in proximal tubule cells
induced by TIO-conditioned media [128]. Although the
antisera clearly recognizes MEPE, it is also possible that
the sera contains antibodies to proteins such as FGF23
and/or FRP4 that may be present at undetectable but
physiologically relevant levels in circulation. Recombi-
nant mammalian-derived MEPE protein failed to inhibit
phosphate transport in vitro [124] or to elicit a phospha-
turic response in normal mice [125]. In contrast, Rowe
et al reported that MEPE generated in insect cells led
to a significant decrease in serum phosphate levels and
increased phosphate excretion when injected into mice
[abstract; Rowe P, J Bone Miner Res 17:S211, 2002].
Furthermore, implantation of CHO-MEPE cells into
nude mice also led to a reduction in serum phosphate and
1a,25(OH)2D3 levels, and increased phosphate excre-
tion. The reason for the discrepancy among these results
is not clear but it is possible that various protein prepara-
tions contained different post-translation modifications.
Importantly, MEPE knockout animals have increased
bone density but do not have altered serum phosphate
levels [151, 152]. This result suggests that MEPE’s poten-
tial effect on phosphate homeostasis may be overcome by
the more general actions of PTH and 1a,25(OH)2D3 or
alternatively may be secondary to the actions of another
phosphatonin.
MEPE is most abundantly expressed in bone tissue
[130, 153]. Argiro et al [153] demonstrated that MEPE
expression in an osteoblast line, MC3T3-E1 is signifi-
cantly induced in mineralizing cultures incubated with
b-glycerophosphate suggesting MEPE may have a role in
mineralization. Furthermore, MEPE knockout animals
have increased bone density [151]. Taken together, these
results imply that the primary function of MEPE is to
control bone mineralization rather than alter renal phos-
phate reabsorption.
ONE OR MORE “PHOSPHATONINS”
It is not possible to definitely designate one or all
three of the proteins described above as the clas-
sic phosphatonin fulfilling all the criteria as originally
defined [77]. Each of the proteins has been found to
inhibit uptake in vitro, promote phosphaturia in vivo,
and are each associated with at least one of the hypophos-
phatemic, hyperphosphaturic disorders (Table 3). FGF23
and FRP4 have been shown to inhibit the normal increase
in 1,25(OH)2D3 concentrations typically induced by
hypophosphatemia. Preliminary evidence also suggests
that MEPE may also control 1,25(OH)2D3 concentra-
tions. The case that FGF23 is the sole phosphatonin is
dramatically weakened by the observation that elevated
circulating FGF23 concentrations are not always corre-
lated with the hypophosphatemic rickets/osteomalacia
disorders. Furthermore, FGF23 is also elevated under
conditions unrelated to these disorders such as humoral
hypercalcemia [141]. Determination of potential circulat-
ing levels of MEPE and/or FRP4 in normal and diseased
patients may ultimately resolve this paradox.
For the time being, it is reasonable to assume that all
three proteins might play a role in the hypophosphatemic
syndromes. However, the term, phosphatonin, may need
to be redefined when a more complete understanding
of the functional impact of each of these three proteins
within temporal and spatial context of the whole organ-
ism is available. It is possible that all three proteins work
synergistically or in a sequential manner to exert phos-
phatonin activities. Alternatively, each protein may elicit
only a subset of the phosphatonin activities such that all
three proteins contribute to the disease symptoms as-
sociated with overexpression of the phosphaturic pro-
teins. Currently, various groups are working relatively
independently to unravel the functional characteristics
of phosphatonin candidates. A complete and accessible
set of reagents for each of the three proteins and studies
focused on the interactions of these proteins through
physical and functional interactions would contribute
greatly to the advancement of this field.
THE PHEX CONNECTION
An area of intense interest and debate is the relation-
ship between PHEX and the phosphatonin activity. In
Schiavi and Kumar: Phosphatonins and phosphate Someostasis 9
Table 3. Comparison of phosphatonin candidate proteins:fibroblast growth factor 23 (FGF23), frizzled-related protein 4 (FRP4), and matrix
extracellular phosphoglycoprotein (MEPE)
FGF23 FRP4 MEPE
Size Intact 30 kD form; processed 12
and 18 kD
40–50 kD 56–58 kD
Cellular location Secreted Secreted Secreted
Structure Member of fibroblast growth
factor family
Member of frizzled-related protein
family
Member of SIBLINGS family
Expression Thyroid, liver, brain, osteoblast Widely expressed, including kidney Expressed predominantly in
osteoblasts
Relation to
hypophosphatemic
disorders
Activating mutation in ADHR
patients; overexpression in TIO
patients; increased serum levels
in some XLH patients
Overexpression in some TIO tumors;
circulating
Overexpression in TIO tumors;
not known if circulating
Demonstrated functions Inhibits renal phosphate
transport; decreases
1a-hydroxylase activity and the
production of 1,25(OH)2D
Inhibits renal phosphate transport in
vitro and in vivo; inhibits induction
of 1a-hydroxylase mRNA and
1,25(OH)2D by low Pi
Alters renal phosphate transport;
modulates 1a-hydroxylase
activity and the production of
1,25(OH)2D
Abbreviations are: SIBLINGS, small integrin-binding ligand, N-linked glycoprotein; ADHR, autosomal-dominant hypophosphatemic rickets; TIO, tumor-induced
osteomalacia; XLH, X-linked hypophosphatemic rickets.
1995, PHEX was identified as the gene defective in XLH
patients [154]. PHEX was found to have significant ho-
mology to a family of endopeptidases that play promi-
nent roles in either activation or inactivation of peptide
factors through proteolytic modification. Although there
is significant heterogeneity in the types of mutations as-
sociated with PHEX, each of the mutations appears to
result in loss of functional PHEX at the osteoblast surface
[155–157]. To reconcile preexisting evidence that XLH
patients and the murine counterpart, the hyp mouse, con-
tain elevated levels of a circulating phosphaturic factor
[117–120, 158], the consortium proposed that the primary
role of PHEX is to cleave and inactivate phosphatonin
[154]. The absence of functional PHEX would presum-
ably lead to either inappropriately expressed or elevated
levels of circulating phosphatonin. An alternative view
is that one or more of the phosphatonins regulates the
PHEX substrate(s).
Although degradation by PHEX has never been a
requirement for classifying a factor as phosphatonin,
it is clear that demonstrating a phosphaturic factor is
inactivated when cleaved would make it a stronger
candidate. Consistent with the premise that FGF23 is
indeed a phosphatonin, crude in vitro proteolysis stud-
ies have demonstrated that wild-type FGF23 levels are
reduced when coexpressed with PHEX in vitro [124].
Although intact FGF23 is too large to be cleaved by
PHEX, it was presumed that smaller FGF23-derived frag-
ments were produced by enzymes present in the lysates.
The inability of PHEX to cleave the nonprocessed mutant
form of FGF23 suggested that one or both of the pro-
cessed fragments may be the preferred substrate(s) for
PHEX (Fig. 3). In a recent in vitro study, several small
FGF23-derived peptides were cleaved by purified solu-
ble PHEX, thereby identifying several potential PHEX
cleavage sites on FGF23 [159, 160]. There was no differ-
ence in the specificity of cleavage between the soluble
or a membrane-associated PHEX. In a second study, a
different FGF23-derived peptide was used as substrate
and obvious cleaved fragments were not observed [161].
The fragment used in the study did include one of the
predicted PHEX cleavage sites but the detection method
may have been insufficient to differentiate between an
intact versus PHEX cleaved product.
Based on these data, we and others have proposed a
model that explains the relationship of FGF23 and PHEX
in XLH, ADHR, and TIO [75, 78, 79, 112] (Fig. 3). The
model is based on the observations that intact FGF23
or ADHR mutant forms can elicit actions on phosphate
transport and 1,25(OH)2D3 synthesis but the model also
assumes that FGF23 processing is a prerequisite for cleav-
age and subsequent inactivation by PHEX. Thus in TIO,
PHEX cannot efficiently cleave the elevated amounts of
FGF23 produced by tumors. In the case of ADHR, mu-
tations lead to increased activity and stability by pre-
venting processing and downstream PHEX cleavage.
Finally, in individuals with XLH, FGF23 concentrations
remain elevated as PHEX is unavailable for regulation.
The apparent role for FGF23 processing is paradoxic
since biologic functions for amino and/or carboxy FGF23
fragments, the by-products of FGF23 processing, have not
been defined. Identification of specific functions for these
fragments coupled to demonstration that they are inacti-
vated by PHEX cleavage will be necessary to definitely
demonstrate that FGF23 is a direct target for PHEX.
While the debate remains regarding PHEX and
FGF23, several lines of evidence suggest that there may
be more than one PHEX substrate and that the patho-
physiology of these disorders may not be explained
by overexpression and/or increased activity of a single
molecule. TIO tumors overproduce multiple proteins,
including FGF23, FRP4, and MEPE. Although FGF23
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is the only protein to date that has been linked to all
three disorders, elevated levels or activity are not al-
ways correlated with hypophosphatemia. Hyp-derived
osteoblasts transplanted into a normal mouse fail to de-
velop into normal mineralized bone suggesting that the
PHEX-deficient osteoblasts can not respond to normal
circulating levels of peptide factors such as FGF23 [163,
164]. Hyp-derived osteoblasts fail to mineralize normally
in vitro [165], further suggesting that PHEX mutations
result in an intrinsic bone defect. Consistent with alter-
ations in mineralization potential is the observation that
hyp-derived osteoblasts express reduced levels of multi-
ple matrix-associated proteins important for the mineral-
ization process [166]. Conditioned media from hyp bone
marrow cells produce a factor(s) that appears to impart
mineralization defects in bones in a normal mouse [139]
and can inhibit renal phosphate transport in vitro [167,
168]. It is not yet known if the same or multiple factors
are responsible for the effects on osteoblast mineraliza-
tion and renal Pi transport.
The data suggesting a role of MEPE in control of min-
eralization and the observation that MEPE mRNA is
elevated in hyp-derived osteoblasts raise the possibil-
ity that MEPE may also be a PHEX substrate [153].
Although in vitro cleavage studies indicate that intact
MEPE is not a PHEX substrate [124, 162], recent data
suggest that PHEX may regulate the cleavage of MEPE
by a cathepsin D–type processing enzyme [162]. In a sep-
arate study, purified PHEX cleaved small MEPE-derived
peptides in vitro, but like FGF23, biologic functions
have not yet been identified for MEPE fragments [160].
Interestingly, transplantation of CHO lines coexpress-
ing MEPE and PHEX do not induce hypophosphatemia,
whereas CHO lines expressing only MEPE cause phos-
phaturia and hypophosphatemia in nude mice [abstract;
Rowe P, J Bone Miner Res 17:S211, 2002]. These studies
suggest that there is indeed a relationship between MEPE
and PHEX but it does not address whether PHEX con-
trols MEPE activity or the activity of a protein regulated
by MEPE.
PHOSPHATONINS AND NORMAL PHYSIOLOGY
Do phosphatonins contribute to the overall balance
of phosphate traditionally considered to be regulated
by 1a,25(OH)2D and PTH? The current data provide
only hints of the importance of this pathway. One would
expect a phosphate-regulating hormone to circulate in
detectable amounts. Unlike the majority of FGF family
members, detectable levels of FGF23 are present in nor-
mal individuals at circulating levels of less than 50 pg/mL.
A second line of evidence that FGF23 might play a role in
normal physiology is the potential regulation of FGF23
expression by changes in serum phosphate levels. A sig-
nificant increase in intact FGF23 was observed in rats fed
a high phosphate diet whereas a decrease in levels was ob-
served after a low phosphate diet [abstract; Yamashita T,
J Am Soc Nephrol 13:577A, 2002]. Small, yet statistically
significant, changes in serum FGF23 concentrations were
observed using the ELISA against the carboxy fragment
in a group of normal humans fed a diet of escalating phos-
phate concentrations [abstract; Allen HC, J Bone Miner
Res 17:S279, 2002]. These results are consistent with the
possibility that FGF23 action is controlled by phosphate.
The finding that targeted ablation of FGF23 in mice leads
to hyperphosphatemia is surprising since the actions of
PTH would be expected to normalize phosphate levels
[abstract; Shimada T, J Bone Miner Res 17:S1159, 2002].
These results suggest that FGF23 may play a general
role in phosphate homeostasis. By extension, additional
proteins within the phosphatonin pathway may also be
important in normal physiological control of serum Pi.
FRP4 has been shown to also be a circulating protein
but Pi changes in its level have not yet been analyzed in
patients with dysregulated phosphate. An understanding
of how each of the phosphatonin pathway components in-
teract with each other, as well as PTH and 1a,25(OH)2D3,
will provide a clearer understanding of how the body con-
trols phosphate.
THE PHOSPHATONIN PATHWAY IN CHRONIC
KIDNEY DISEASE
Finally, it is relevant to consider the contribution of
the phosphatonin pathway in chronic kidney disease. It
is well recognized that the progression of chronic kid-
ney disease results in decreased circulating levels of
1a,25(OH)2D3 followed by increased serum concentra-
tions of PTH and ultimately elevated levels of serum
phosphate [169]. FGF23 is also elevated in individuals
with end-stage renal disease [139]. This result is consis-
tent with potential regulation of FGF23 by elevated Pi
associated with late stages of chronic kidney disease. It
is possible, that like PTH, FGF23 is induced as part of a
compensatory mechanism that is induced with declining
renal function. Alternatively, FGF23 increases may re-
flect decreasing clearance by the damaged kidney. Addi-
tional investigation will be required to determine whether
the pathophysiology of chronic kidney disease results in
dysregulation of FGF23 or FGF23 plays a causal role in
chronic kidney disease.
CONCLUSION
The growing evidence that several molecules are asso-
ciated with hypophosphatemia in individuals with XLH,
ADHR, and TIO and evidence for distinct phosphate-
regulating factors associated with other disorders [75]
suggest that phosphatonins represent a new class of se-
creted factors that control phosphate homeostasis. These
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proteins may contribute to global regulation of serum
phosphate concentrations by directly inhibiting renal
phosphate transport or indirectly through the control of
bone mineralization. The need to maintain average levels
of phosphate between 2.5 to 4.5 mg/dL is clearly exem-
plified by the deleterious effects of sustained hypophos-
phatemia or hyperphosphatemia. Of equal importance
is the need to have localized control of phosphate. Pi is
known to specifically regulate cell changes such as gene
expression and apoptosis [170, 171]. The existence of mul-
tiple phosphatonins, such as FGF23, FRP4, and MEPE,
that have distinct and overlapping functions provides the
flexibility to maintain a relative balance in serum phos-
phate while fine-tuning local phosphate concentrations
to meet the needs at a specific site.
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